Treatment for Subjects With Chronic Kidney Disease (CKD) Not Receiving Dialysis
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
The proposed study is designed to test a novel dosing paradigm that would facilitate the
treatment of anemia in CKD patients not on dialysis. Anemic patients who have achieved and
maintained target hemoglobin (Hb) on every 2 weeks (Q2W) dosing of darbepoetin alfa will have
the dosing interval extended to once monthly (QM) dosing. Extending the dosing interval for
darbepoetin alfa to QM represents a major potential benefit to both patients with CKD and
their caregivers.